Paclitaxel by 72-Hour Continuous Infusion Followed by Bolus Intravenous Ifosfamide or Epirubicin: Results of Two Phase I Studies

Publisher： Karger

E-ISSN： 1423-0232|60|2|116-122

ISSN： 0030-2414

Source： Oncology, Vol.60, Iss.2, 2001-02, pp. : 116-122

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Dose Finding of Ifosfamide Administered with a Chronic Two-Week Continuous Infusion

By  

Oncology, Vol. 65, Iss. 2, 2003-11 ,pp. : 31-36

Karger

Access to resources Recommend Favorite

Comparison of 1-Hour and 3-Hours Paclitaxel Infusion Pharmacokinetics: Results from a Randomized Trial

By  

Oncology Research and Treatment, Vol. 25, Iss. 6, 2003-01 ,pp. : 503-508

Karger

Access to resources Recommend Favorite

Phase II Study of Cisplatin, Epirubicin, and Continuous-Infusion 5-Fluorouracil for Advanced Biliary Tract Cancer

By  

Oncology, Vol. 64, Iss. 4, 2003-05 ,pp. : 475-476

Karger

Access to resources Recommend Favorite

A Phase I Study of Paclitaxel and Epirubicin, without and with Filgrastim, for the Treatment of Platinum-Resistant Advanced Ovarian Cancer

By  

Oncology, Vol. 56, Iss. 4, 1999-05 ,pp. : 267-273

Karger

Access to resources Recommend Favorite

Phase I Study of Biweekly Intravenous Paclitaxel plus Intraperitoneal Cisplatin and Paclitaxel for Gastric Cancer with Peritoneal Metastasis

By  

Oncology, Vol. 79, Iss. 3-4, 2011-03 ,pp. : 269-272

Karger

Access to resources Recommend Favorite